Svetla Gadzhanova1, Jenni Ilomäki, Elizabeth E Roughead. 1. Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute, School of Pharmacy and Medical Sciences, University of South Australia, Frome Road, Adelaide, 5000, Australia. svetla.gadzhanova@unisa.edu.au
Abstract
UNLABELLED: BACKGROUND National guidelines in Australia advise that patients should be stabilised on both individual antihypertensive medicines before initiating a fixed-dose combination (FDC) product. OBJECTIVE: The aim of this study was to examine the antihypertensive medicines use before and after initiation of four antihypertensive FDC products recently listed under the Australian Pharmaceutical Benefits Scheme--olmesartan or valsartan with hydrochlorothiazide, valsartan with amlodipine and ramipril with felodipine. SETTING Australian veteran population METHODS: This was a retrospective cohort study using Australian Government Department of Veterans' Affairs pharmacy claims data. Subjects initiating a FDC between 2008 and 2010 were included. Their antihypertensive medicine use was investigated in the 12-months prior to and post FDC product initiation. MAIN OUTCOME MEASURE: Proportions of FDC initiators dispensed one or both of the individual medicines, or who had antihypertensive medicines other than the individual ones were assessed for the 12 months prior to initiation. For the post history, proportions of patients who continued the FDC as a sole therapy, had other antihypertensives co-administered with FDC, or ceased the FDC were established. RESULTS: 2,513 participants initiated one of the four FDC products in the study period. Immediately prior to FDC initiation, below 1 % had both individual medicines, 29 % had one of the individual medicines, 58 % had antihypertensive medicines other than the individual ones, and 12 % had no antihypertensive therapy. At 12 months post initiation, 25 % of the FDC initiators continued it as a sole treatment, 35 % required an additional antihypertensive medicine in addition to FDC product, and 40 % ceased the FDC. CONCLUSION: A minority of patients initiated combination products after being stabilised on both individual medicines. Significant number had no prior history of antihypertensive use. One-third of FDC initiators still required additional antihypertensive medication concurrently with the FDC product at 12 months post initiation.
UNLABELLED: BACKGROUND National guidelines in Australia advise that patients should be stabilised on both individual antihypertensive medicines before initiating a fixed-dose combination (FDC) product. OBJECTIVE: The aim of this study was to examine the antihypertensive medicines use before and after initiation of four antihypertensive FDC products recently listed under the Australian Pharmaceutical Benefits Scheme--olmesartan or valsartan with hydrochlorothiazide, valsartan with amlodipine and ramipril with felodipine. SETTING Australian veteran population METHODS: This was a retrospective cohort study using Australian Government Department of Veterans' Affairs pharmacy claims data. Subjects initiating a FDC between 2008 and 2010 were included. Their antihypertensive medicine use was investigated in the 12-months prior to and post FDC product initiation. MAIN OUTCOME MEASURE: Proportions of FDC initiators dispensed one or both of the individual medicines, or who had antihypertensive medicines other than the individual ones were assessed for the 12 months prior to initiation. For the post history, proportions of patients who continued the FDC as a sole therapy, had other antihypertensives co-administered with FDC, or ceased the FDC were established. RESULTS: 2,513 participants initiated one of the four FDC products in the study period. Immediately prior to FDC initiation, below 1 % had both individual medicines, 29 % had one of the individual medicines, 58 % had antihypertensive medicines other than the individual ones, and 12 % had no antihypertensive therapy. At 12 months post initiation, 25 % of the FDC initiators continued it as a sole treatment, 35 % required an additional antihypertensive medicine in addition to FDC product, and 40 % ceased the FDC. CONCLUSION: A minority of patients initiated combination products after being stabilised on both individual medicines. Significant number had no prior history of antihypertensive use. One-third of FDC initiators still required additional antihypertensive medication concurrently with the FDC product at 12 months post initiation.
Authors: William C Cushman; Charles E Ford; Jeffrey A Cutler; Karen L Margolis; Barry R Davis; Richard H Grimm; Henry R Black; Bruce P Hamilton; Joanne Holland; Chuke Nwachuku; Vasilios Papademetriou; Jeffery Probstfield; Jackson T Wright; Michael H Alderman; Robert J Weiss; Linda Piller; Judy Bettencourt; Sandra M Walsh Journal: J Clin Hypertens (Greenwich) Date: 2002 Nov-Dec Impact factor: 3.738
Authors: Robin L Walker; Guanmin Chen; Norman R C Campbell; Finlay A McAlister; Hude Quan; Karen Tu; Nadia A Khan; Brenda R Hemmelgarn Journal: Can J Cardiol Date: 2011-06-02 Impact factor: 5.223
Authors: Doreen M Rabi; Stella S Daskalopoulou; Raj S Padwal; Nadia A Khan; Steven A Grover; Daniel G Hackam; Martin G Myers; Donald W McKay; Robert R Quinn; Brenda R Hemmelgarn; Lyne Cloutier; Peter Bolli; Michael D Hill; Thomas Wilson; Brian Penner; Ellen Burgess; Maxime Lamarre-Cliché; Donna McLean; Ernesto L Schiffrin; George Honos; Karen Mann; Guy Tremblay; Alain Milot; Arun Chockalingam; Simon W Rabkin; Martin Dawes; Rhian M Touyz; Kevin D Burns; Marcel Ruzicka; Norman R C Campbell; Michel Vallée; G V Ramesh Prasad; Marcel Lebel; Tavis S Campbell; M Patrice Lindsay; Robert J Herman; Pierre Larochelle; Ross D Feldman; J Malcolm O Arnold; Gordon W Moe; Jonathan G Howlett; Luc Trudeau; Simon L Bacon; Robert J Petrella; Richard Lewanczuk; James A Stone; Denis Drouin; Jean-Martin Boulanger; Mukul Sharma; Pavel Hamet; George Fodor; George K Dresser; S George Carruthers; George Pylypchuk; Richard E Gilbert; Lawrence A Leiter; Charlotte Jones; Richard I Ogilvie; Vincent Woo; Philip A McFarlane; Robert A Hegele; Luc Poirier; Sheldon W Tobe Journal: Can J Cardiol Date: 2011 Jul-Aug Impact factor: 5.223
Authors: H A J Struijker-Boudier; E Ambrosioni; H Holzgreve; S Laurent; G Mancia; L M Ruilope; B Waeber Journal: Int J Clin Pract Date: 2007-09 Impact factor: 2.503